Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on July 14, 2008. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Mr. Amos Bar-Shalev as a director of the Company. He was appointed to serve until the next annual meeting of shareholders. Additionally, Mr. Bar-Shalev was appointed to replace Mr. Eyal Sheratzky on both the Audit Committee and the Compensation Committee.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The appointment was made in accordance with Article V, Section 2 of the Company's ByLaws.
Key Facts for Investor Verification
- Mr. Amos Bar-Shalev was appointed as a director on July 14, 2008.
- Mr. Bar-Shalev replaces Mr. Eyal Sheratzky on the Audit and Compensation Committees.
- Mr. Bar-Shalev previously served as a director of the Company from December 31, 2006, until the last annual meeting but was not nominated for re-election at that time.
- Mr. Bar-Shalev has been a director of Protalix Ltd., a wholly-owned subsidiary, since 2005.